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Comments, Observations, and Rebuttals
Response to Misused and Misleading: 100% Response Rate  
to Galcanezumab in Patients With Episodic Migraine
We thank the authors of the letter for sharing their 
views on this article. We pursued the publishing of 
these data in an attempt to clearly define and further 
characterize patients with a monthly response rate of 
100% to galcanezumab. The purpose of this article was 
to dispel the very notion that a significant number of 
patients had 100% response across the entire treatment 
period, which the authors of the Letter to the Editor 
raised. The title is meant to reflect the article content 
related to the characterization of patients with epi-
sodic migraine who achieved 100% monthly response 
(ie, 100% reduction from baseline in monthly migraine 
headache days) to galcanezumab treatment. The use 
of the terms “response rate” and “responder rates” 
is standard terminology used in clinical trials/clini-
cal trial guidelines for migraine preventive therapies 
(http://www.ihs-headache.org/binary_data/158_clin-
ical-trials-controlled-trials-of-drugs-in-migraine- 
3rd-ed-cha.pdf). Whether speaking of ≥50%, ≥75%, or 
100% reduction of migraine headache days, the terms 
“response rate” and “responder rates” are common 
and appropriate terminology to use.
We disagree with the suggestion by the authors’ 
Letter to the Editor that the month-by-month analysis 
was unconventional or the results presented, which in-
cluded the odds ratios, were misleading. The primary 
and secondary outcomes for these trials, such as the 
number of monthly migraine headache days and the 
proportions of patients with ≥50%, ≥75%, or 100% re-
sponse, were measured monthly (at each visit). These 
outcomes capture the patients’ response during any 
given month between 2 separate doses. In this paper, 
we presented the observed as well as the model-esti-
mated number and proportions of patients with 100% 
response at each month (Supplemental Table S1 and 
Fig. 1, respectively) from a generalized linear mixed 
effects model estimate. This well-accepted model is a 
robust method of analyzing longitudinal data in clin-
ical trials and is basically a mixed-models repeated 
measures version of a logistic regression (a standard 
analysis approach for binary outcomes for which odds 
ratios are readily available). The primary analysis 
approach of looking at the average across months 
yields a standard measure of monthly response seen by 
patients across the entire dosing month period. Such 
an estimate is neither biased toward higher  response 
seen in the later months of treatment nor overly 
 penalized by the lower responses observed in the ear-
lier months of treatment. What is represented is the 
estimated proportions of patients who are  expected to 
have a 100% response (ie, 0 migraine headache days) 
on an average month (averaged across all visits) and is 
not the same as the proportions of  patients with 100% 
response in any 1 out of the 6 months. The proportions 
of patients with at least 1 month with 100% response 
is approximately 40%. In addition to presenting the 
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raw month-by-month numbers, we also present odds 
ratios of 100% response for treatment compared to 
placebo, which is a standard output for logistical re-
gression analyses. There was no intention to mislead 
the readers, but rather to provide results as is stan-
dard for these types of data. Therefore, we do not 
agree with the authors’ suggestion that the outcome 
measured is of “very questionable worth.” To the con-
trary, although the new analyses in the manuscript 
are post hoc (and were indicated as such), and should 
be interpreted as such, we believe that they provide 
clinicians with better insight into what patients might 
expect. We feel it is more relevant for a clinician to 
inform a patient with episodic migraine that in 2 clin-
ical trials, a given percentage of patients had at least 
1, 2, 3, or more months of migraine freedom than a 
population-level assessment of 100% response rates in 
an average month.
In conclusion, we do feel that a possibility of 100% 
response in any given month with galcanezumab treat-
ment may be very significant to patients. With 14% of 
patients on galcanezumab treatment achieving 100% 
response vs 6% on placebo, the numbers needed to 
treat (NNT) to have 1 additional person with a 100% 
monthly response would be 12 to 13 (specifically 12.5). 
This is much more realistic than an NNT = 125, which 
would represent 6 consecutive months of migraine free-
dom from the onset of treatment. We sincerely  believe 
that this article provides further characterization that 
should allow clinicians to set appropriate expectations 
regarding the efficacy of galcanezumab in patients with 
episodic migraine. We appreciate the authors of the let-
ter for providing us the opportunity to clarify.
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Fig. 1.—Patients with 100% response by month. N = sample size for treatment group. [Colour figure can be viewed at 
wileyonlinelibrary.com]
